menu
    • menu

    Company profile for TuHURA Biosciences

    NEW Drugs in Dev: 1
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TuHURA Biosciences is a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy. Its lead candidate, IFx-2.0, is designed to enhance the efficacy of checkpoint inhibitors and is set for a Phase 3 trial with Keytruda® in advanced Merkel Cell Carcinoma. Additionally, TuHURA is developing first-in-class bi-specific ADCs and PDCs targeting Myeloid Derived Suppressor Cells to prevent T cell exhaust...
    TuHURA Biosciences is a Phase 3 immuno-oncology company focused on overcoming resistance to cancer immunotherapy. Its lead candidate, IFx-2.0, is designed to enhance the efficacy of checkpoint inhibitors and is set for a Phase 3 trial with Keytruda® in advanced Merkel Cell Carcinoma. Additionally, TuHURA is developing first-in-class bi-specific ADCs and PDCs targeting Myeloid Derived Suppressor Cells to prevent T cell exhaustion and acquired resistance, advancing novel therapies to improve patient outcomes in cancer treatment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TuHURA BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10500 University Center Drive Suite 110 Tampa FL 33612
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://tuhurabio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tuhurabio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TuHURA Presents DOR as ICI Resistance Target at 57th ASH Meeting
    TuHURA Presents DOR as ICI Resistance Target at 57th ASH Meeting

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-presents-data-demonstrating-the-delta-opioid-receptor-dor-as-a-new-target-in-overcoming-acquired-resistance-to-immune-checkpoint-inhibitors-at-the-57th-ash-annual-meeting-and-exposition-302634833.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Tuhura Biosciences Targets (DOR) To Reprogram MDSCs at ASH
    Tuhura Biosciences Targets (DOR) To Reprogram MDSCs at ASH

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-discovery-research-on-targeting-the-delta-opioid-receptor-dor-to-reprogram-myeloid-derived-suppressor-cells-mdscs-selected-for-oral-presentation-at-the-67th-ash-annual-meeting-and-exposition-302602298.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    TuHURA Biosciences to Speak at 27th HC Wainwright Conference
    TuHURA Biosciences to Speak at 27th HC Wainwright Conference

    20 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-to-present-at-the-27th-annual-hc-wainwright-global-investment-conference-302533745.html

    PR NEWSWIRE
    20 Aug 2025
    Share Share
    TuHura Biosciences Reports Q2 2025 Financials, Corporate Update
    TuHura Biosciences Reports Q2 2025 Financials, Corporate Update

    14 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update-302530551.html

    PR NEWSWIRE
    14 Aug 2025
    Share Share
    TuHURA Biosciences Joins Russell 3000 and Russell 2000 Indexes
    TuHURA Biosciences Joins Russell 3000 and Russell 2000 Indexes

    01 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-inc-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes-302495694.html

    PR NEWSWIRE
    01 Jul 2025
    Share Share
    TuHURA Biosciences Completes Acquisition of Kineta
    TuHURA Biosciences Completes Acquisition of Kineta

    30 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tuhura-biosciences-completes-acquisition-of-kineta-302494115.html

    PR NEWSWIRE
    30 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search